The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: And next for the comments on how to think about SKYTROFA sales this year. Can you comment on your comfort level with consensus estimates
for TransCon PTH this year? And actually, while we're at it, where is that consensus figure based on your latest compilation of the analyst numbers?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
FEBRUARY 16, 2023 / 9:30PM, ASND.OQ - Q4 2022 Ascendis Pharma A/S Earnings Call
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: For PTH.
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: Okay. I'm going to ask something else then. Can you tell us how many cumulative new patient prescriptions there were for SKYTROFA as of year-end?
I think you were previously giving that quarter-by-quarter. And can you also tell us when we should look for the next update from the Phase II
extension for TransCon CNP?
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: Well, I think in the past, you talked about the height velocity for a proportion of patients that had been on out to a certain time point, and I think
we're going to maybe update that when all of the patients got out to that time point. Is there kind of a plan to update that data? And when should
we expect it?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
FEBRUARY 16, 2023 / 9:30PM, ASND.OQ - Q4 2022 Ascendis Pharma A/S Earnings Call
Question: Andreas Argyrides - Wedbush Securities Inc., Research Division - Analyst
: So when you're thinking about -- this is for PTH, when you're thinking about the opportunity to launch and the opportunity in PTH, how are you
thinking about it compared to the NATPARA launch? And then maybe you can give us some insights on how NATPARA coming off the market at
the end of '23 is informing your expectations for the launch? And then I have a follow-up.
Question: Andreas Argyrides - Wedbush Securities Inc., Research Division - Analyst
: Okay. Great. That's helpful. And maybe -- okay, I guess maybe the opportunity that there is no approved product on the market. There were some
patients mostly in Europe as well, but you still on it or had access to it no longer. Are those going to be early adopters or yes. And...
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
FEBRUARY 16, 2023 / 9:30PM, ASND.OQ - Q4 2022 Ascendis Pharma A/S Earnings Call
Question: Andreas Argyrides - Wedbush Securities Inc., Research Division - Analyst
: Okay. Great. And then just a quick one on SKYTROFA. And maybe you can elaborate and I don't know if you covered this already, sorry, if you did,
and I missed it, but if you can elaborate on the launch dynamics that are driving growth, are you seeing higher switch rates from daily growth
hormone?
| 
